Antibe Therapeutics Inc.
Antibe Therapeutics Inc., a pioneering biopharmaceutical company headquartered in Canada, focuses on developing innovative therapies for pain management and inflammation. Founded in 2010, Antibe has made significant strides in the industry, particularly with its lead product, ATB-346, which aims to provide safer alternatives to traditional non-steroidal anti-inflammatory drugs (NSAIDs). With a commitment to enhancing patient outcomes, Antibe's unique approach combines its proprietary hydrogen sulfide (H2S) technology with established drug compounds, setting it apart in the competitive landscape. The company has garnered attention for its promising clinical results and strategic partnerships, positioning itself as a key player in the pain management sector. As Antibe continues to advance its pipeline, it remains dedicated to addressing unmet medical needs and improving the quality of life for patients worldwide.
DitchCarbon Score
How does Antibe Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Antibe Therapeutics Inc.'s score of 13 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Antibe Therapeutics Inc.'s reported carbon emissions
Antibe Therapeutics Inc., headquartered in CA, currently does not have any available carbon emissions data for recent years, as no specific emissions figures have been reported. Consequently, there are no defined reduction targets or climate commitments outlined by the company at this time. In the absence of concrete data, it is essential to note that many companies in the pharmaceutical sector are increasingly focusing on sustainability and climate action, often setting ambitious targets to reduce their carbon footprint. However, without specific information from Antibe Therapeutics, it is unclear what initiatives or commitments they may have in place regarding carbon emissions and climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Antibe Therapeutics Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
